FORM 4

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response. 0.5

	,			,
Name and Address of Reporting Per Omenn, Gilbert S.	rson*	2. Issuer Name and Ticker or Trading Symbol	Statement for Month/Day/Year	6. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) One Amgen Center Drive	(Middle)	AMGEN INC. (AMGN)	12/30/2002	X Director _ 10% Owner _ Officer (give title below) _ Other (specify below)
(Street) Thousand Oaks,, CA 91320-1799		3. I.R.S. Identification Number of Reporting Person. if an entity	5. If Amendment, Date of Original	Description
(City) (State)	(Zip)	(voluntary)	(Month/Day/Year)	7. Individual or Joint/Group Filing (Check Applicable Line)
				X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3)	2.Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Trans Code (Instr		4. Securities Acquirer (Instr. 3, 4, and 5)	d (A) or Disposed Of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Owner-ship Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	A/D	Price	(Instr. 3 and 4)				
Common Stock	12/30/02		G	V	16,000	D	\$0	141,064	D			
Common Stock								5,250	ı	By Son		
Contractual Contingent Payment Rights								/1/ 0.5	D			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/ Day/ Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	Code	4. Transaction Code (Instr.8) 5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			6. Date Exercisable(DE) and Expiration Date(ED) (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr.5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.4)	10. Owner- ship Form of Deriv- ative Securities: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr.4)
				Code	v	A	D	DE	ED	Title	Amount or Number of Shares			(Instr.4)	

Explanation of Responses:

Name: Omenn, Gilbert S One Amgen Center Drive Thousand Oaks CA 91320-1799 Statement for Month/Day/Year: 12/30/2002 Issuer Name: Amgen Inc. (AMGN)

Note: 1 (GO-CCPR) Contractual contingent payment rights arising from the purchase by Amgen Inc. of two Class A interests of Amgen Clinial Partners, L.P.

By:

/s/ Lawrence M. Furst Attorney-in-fact

** Signature of Reporting Person

Date

12-30-02

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC 1474 (9-02)